Unlock LNP potential with enhanced clinical translatability at the 3rd Lipid Nanoparticles Development Summit Europe (24-26 September, Berlin, Germany), the leading dedicated LNP f
2024 has started off with a bang with recent back-to-back positive results for gene therapy for rare genetic hearing disorders and major headways in otoprotective, restorative and regenerative smal
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
